References
- 1Baizabal-Carvallo JF, Morgan JC. Drug-induced tremor, clinical features, diagnostic approach and management. Journal of the neurological sciences. 2022; 435: 120192. DOI: 10.1016/j.jns.2022.120192
- 2Morgan JC, Kurek JA, Davis JL, Sethi KD. Insights into Pathophysiology from Medication-induced Tremor. Tremor and other hyperkinetic movements (New York, NY). 2017; 7: 442. DOI: 10.5334/tohm.374
- 3Shrestha BM. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences. Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation. 2017; 15: 1–9.
- 4Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artificial organs. 2020; 44: 140–152. DOI: 10.1111/aor.13551
- 5Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. The New England journal of medicine. 2007; 357: 2562–2575. DOI: 10.1056/NEJMoa067411
- 6KDIGO clinical practice guideline for the care of kidney transplant recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009; 9(Suppl 3): S1–155. DOI: 10.1111/j.1600-6143.2009.02834.x
- 7Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997; 63: 977–983. DOI: 10.1097/00007890-199704150-00013
- 8Azzi JR, Sayegh MH, Mallat SG.
Calcineurin inhibitors: 40 years later, can’t live without . Journal of immunology. (Baltimore, Md: 1950) 2013; 191: 5785–5791. DOI: 10.4049/jimmunol.1390055 - 9Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant international: official journal of the European Society for Organ Transplantation. 2000; 13: 313–326. DOI: 10.1111/j.1432-2277.2000.tb01004.x
- 10Bulatova N, Yousef AM, Al-Khayyat G, Qosa H. Adverse effects of tacrolimus in renal transplant patients from living donors. Current drug safety. 2011; 6: 3–11. DOI: 10.2174/157488611794480043
- 11Anghel D, Tanasescu R, Campeanu A, Lupescu I, Podda G, Bajenaru O. Neurotoxicity of immunosuppressive therapies in organ transplantation. Maedica. 2013; 8: 170–175.
- 12Bhatia KP, Bain P, Bajaj N, et al. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Movement disorders: official journal of the Movement Disorder Society. 2018; 33: 75–87. DOI: 10.1002/mds.27121
- 13Fahn STE, Marin C. Clinical rating scale for tremor. Parkinson’s disease and movement disorders. 1993; 2: 271–280.
- 14Ondo WG, Shukla AW, Ondo C. TETRAS Spirals and Handwriting Samples: Determination of Optimal Scoring Examples. Tremor and other hyperkinetic movements (New York, NY). 2021; 11: 50. DOI: 10.5334/tohm.665
- 15Erro R, Bacchin R, Magrinelli F, et al. Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients. Journal of neurology. 2018; 265: 1676–1683. DOI: 10.1007/s00415-018-8904-x
- 16Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Movement disorders: official journal of the Movement Disorder Society. 1998; 13(Suppl 3): 2–23. DOI: 10.1002/mds.870131303
- 17Paul F, Müller J, Christe W, Steinmüller T, Poewe W, Wissel J. Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy. Clinical transplantation. 2004; 18: 429–433. DOI: 10.1111/j.1399-0012.2004.00184.x
- 18Langone A, Steinberg SM, Gedaly R, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clinical transplantation. 2015; 29: 796–805. DOI: 10.1111/ctr.12581
- 19Jabarkheel Z, Wagle Shukla A. Essential requisites for rest tremor assessment in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society. 2019; 34: 927–929. DOI: 10.1002/mds.27711
- 20Lakie M, Walsh EG, Arblaster LA, Villagra F, Roberts RC. Limb temperature and human tremors. Journal of neurology, neurosurgery, and psychiatry. 1994; 57: 35–42. DOI: 10.1136/jnnp.57.1.35
- 21Wagle Shukla A, Okun M, Vaillancourt D, Warren L. The ice test to differentiate essential tremor from Parkinson’s disease tremor. Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. 2017; 128: 2181–2183. DOI: 10.1016/j.clinph.2017.08.015
- 22Cooper C, Evidente VG, Hentz JG, Adler CH, Caviness JN, Gwinn-Hardy K. The effect of temperature on hand function in patients with tremor. Journal of hand therapy: official journal of the American Society of Hand Therapists. 2000; 13: 276–288. DOI: 10.1016/S0894-1130(00)80019-8
- 23Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA. FK506-induced neurotoxicity in liver transplantation. Annals of neurology. 1994; 35: 498–501. DOI: 10.1002/ana.410350422
- 24Uemoto S, Tanaka K, Honda K, et al. Experience with FK506 in living-related liver transplantation. Transplantation. 1993; 55: 288–292. DOI: 10.1097/00007890-199302000-00011
- 25Choi D, Thaker S, West-Thielke P, Elmasri A, Chan C. Evaluating the conversion to extended-release tacrolimus from immediate-release tacrolimus in liver transplant recipients. European journal of gastroenterology & hepatology. 2021; 33: 1124–1128. DOI: 10.1097/MEG.0000000000002172
- 26Turunc V, Ari E, Guven B, Tabendeh B, Yildiz A. Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience. Transplantation proceedings. 2019; 51: 2308–2311. DOI: 10.1016/j.transproceed.2019.01.149
- 27Wagle Shukla A. Rationale and Evidence for Peripheral Nerve Stimulation for Treating Essential Tremor. Tremor and other hyperkinetic movements; 2022. DOI: 10.5334/tohm.685
- 28Wagle Shukla A. Reduction of neuronal hyperexcitability with modulation of T-type calcium channel or SK channel in essential tremor. International review of neurobiology. 2022; 163: 335–355. DOI: 10.1016/bs.irn.2022.02.008
